Co-Diagnostics (CODX) Stock Statistics & Valuation Metrics

Co-Diagnostics has a market cap or net worth of $12.82M. The enterprise value is $381.06M.

Co-Diagnostics has 2,095,031 shares outstanding. The number of shares has decreased by -2.65% in one year.

Co-Diagnostics’s return on equity (ROE) is -0.69 and return on invested capital (ROIC) is -69.59%.

The current PE Ratio of Co-Diagnostics is ―. Co-Diagnostics’s PEG ratio is -5.44.

In the last 12 months, Co-Diagnostics had revenue of 3.92M and earned -37.64M in profits. Earnings per share was -37.20.

In the last 12 months, operating cash flow was -31.17M and capital expenditures -641.07K, giving a free cash flow of -31.81M billion.

Co-Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―

Co-Diagnostics upcoming earnings date is Mar 19, 2026, Before Open (Confirmed).

Co-Diagnostics as a current ratio of 4.41, with Debt / Equity ratio of 3.70%

In the past 12 months, Co-Diagnostics has paid 57.37K in taxes.

Co-Diagnostics EV to EBITDA ratio is -17.61, with an EV/FCF ratio of -22.80.

Co-Diagnostics has $11.44M in cash and marketable securities with $1.47M in debt, giving a net cash position of $9.97M billion.

Gross margin is 34.03%, with operating margin of -1023.75%, and net profit margin of -961.37%.

The average price target for Co-Diagnostics is $1.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy